SCHEMBL21617191

SCHEMBL21617191

COC(=O)c1ccccc1Nc1ccc(OCc2ccccc2)cc1C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSV O60911 2/20 0.51
▸ CTSL P07711 2/20 0.51
▸ KDM4E B2RXH2 5/20 0.49
▸ HPGD P15428 4/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ MAPT P10636 3/20 0.49
▸ SIRT2 Q8IXJ6 2/20 0.49
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ MAPK10 P53779 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ LMNA P02545 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ KMT2A Q03164 1/20 0.44
▸ ALOX5AP P20292 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33372525 1.00 CTSV (0.51) CTSVCTSLKDM4EHPGDALDH1A1
SCHEMBL21617230 0.91 CTSV (0.62) CTSVCTSLKDM4ESIRT2MAOB
SCHEMBL31504338 0.91 CTSV (0.62) CTSVCTSLKDM4ESIRT2MAOB
SCHEMBL10833856 0.80 SIRT2 (0.74) CTSVCTSLKDM4EHPGDALDH1A1
SCHEMBL31504355 0.79 MAOB (0.46) CTSVCTSLALDH1A1MAOBKMT2A
SCHEMBL21617165 0.79 MAOB (0.46) CTSVCTSLALDH1A1MAOBKMT2A
SCHEMBL11563262 0.78 MAOB (0.56) CTSVCTSLKDM4EHPGDALDH1A1
SCHEMBL27568225 0.76 CTSV (0.58) CTSVCTSLKDM4EHPGDALDH1A1
SCHEMBL18648449 0.76 MAOB (0.54) HPGDALDH1A1MAPTLMNAMAOB
SCHEMBL2609089 0.75 MAOB (0.50) CTSVCTSLKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421206-B2 Aryl-n-aryl derivatives for treating a RNA virus infection ABIVAX (FR) 2025-09-23 — — US disclosed
EP-3820850-A1 PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2021-05-19 — — EP disclosed
US-20210122732-A1 ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2021-04-29 — — US disclosed
CN-112638877-A phenyl/pyridyl-N-phenyl/pyridyl derivatives for the treatment of RNA viral infections ABIVAX公司 2021-04-09 — — CN disclosed
WO-2020011816-A1 PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2020-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421206-B2 Aryl-n-aryl derivatives for treating a RNA virus infection NSUN3, CBR3, C1R CTSV 1470/4885CTSL 3640/4885KDM4E 1489/4885
US-20210122732-A1 ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION NSUN3, CBR3, C1R CTSV 1470/4885CTSL 3640/4885KDM4E 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback